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Mycobacterium asiaticum was first reported as a cause of human disease in 1982, with only a few cases in the
literature to date. This study aims to review the clinical significance of M. asiaticum isolates in Queensland,
Australia. A retrospective review (1989 to 2008) of patients withM. asiaticum isolates was conducted. Data were
collected through the Queensland TB Control Centre database. Disease was defined in accordance with the
American Thoracic Society criteria. Twenty-four patients (13 female) had a positive culture of M. asiaticum,
many residing around the Tropic of Capricorn. M. asiaticum was responsible for pulmonary disease (n  2),
childhood lymphadenitis (n  1), olecranon bursitis (n  1), 6 cases of possible pulmonary disease, and 2
possible wound infections. Chronic lung disease was a risk factor for pulmonary infection, and wounds/
lacerations were a risk factor for extrapulmonary disease. Extrapulmonary disease responded to local mea-
sures. Pulmonary disease responded to ethambutol-isoniazid-rifampin plus pyrazinamide for the first 2
months in one patient, and amikacin-azithromycin-minocycline in another patient. While M. asiaticum is rare
in Queensland, there appears to be an environmental niche. Although often a colonizer, it can be a cause of
pulmonary and extrapulmonary disease. Treatment of pulmonary disease remains challenging. Extrapulmo-
nary disease does not mandate specific nontuberculous mycobacterium (NTM) treatment.
Nontuberculous mycobacteria (NTM) have been recognized
as human pathogens since the 1950s (17, 30). Over recent
decades the taxonomy has continued to evolve, and new species
are being recognized. This is attributable to improved methods of
identification, including chemotaxonomic and molecular methods
(11).
Mycobacterium asiaticum was first named by Weiszfeiler et
al., who recognized it as a new slow-growing mycobacterium
species with characteristics separate from those of Mycobacte-
rium simiae and the other slow growers, Mycobacterium kan-
sasii and Mycobacterium marinum (31). It was first reported in
humans in Queensland (QLD), Australia, by Blacklock et al. in
1982, where M. asiaticum was thought to be responsible for
pulmonary disease in 2 of 5 human cases (5). The first case
report of pulmonary disease secondary to M. asiaticum in the
United States was in 1990 (27). These reported patients with
progressive pulmonary disease secondary to M. asiaticum
mostly had an underlying chronic respiratory problem such as
chronic obstructive pulmonary disease (COPD). M. asiaticum
has also been reported to be responsible for extrapulmonary
disease in humans, namely, flexor tenosynovitis (8), olecranon
bursitis (6), and keratitis (7).
Previous studies, with their limitations, have suggested
climate as a factor responsible for the distribution of M.
asiaticum, with an association noted between prevalence of
M. asiaticum and subtropical climates, such as Queens-
land’s, particularly an area of northern Queensland near the
Tropic of Capricorn (5). This association was noted in both
animal and human studies (31).
There are limited data about the antimicrobial susceptibili-
ties of M. asiaticum and response to treatment. Weiszfeiler et
al. reported that M. asiaticum in monkeys is resistant to strep-
tomycin, isoniazid, p-aminosalicylate, and rifampin but suscep-
tible to cycloserine (32). However the use of antituberculosis
therapy, including agents such as isoniazid, rifampin, etham-
butol, pyrazinamide, streptomycin, and capreomycin, yielded
more-encouraging results in humans (5, 27), with clinical re-
sponse not correlating with in vitro susceptibilities. Older fluo-
roquinolones, such as ofloxacin, have also been used, although
M. asiaticum has higher mean inhibitory concentrations than
other slow-growing mycobacteria (15).
The aim of this study was to evaluate isolates of M. asiaticum
in Queensland and describe the incidence and epidemiology of
disease, risk factors, clinical and radiological spectrum, treat-
ments, and outcome.
MATERIALS AND METHODS
We conducted a retrospective review of all cases in which Mycobacterium
asiaticum was isolated in QLD between November 1989 and December 2007. In
QLD all NTM isolates are speciated by a central reference laboratory, the
QLD Mycobacterial Reference Laboratory (QMRL), and are notifiable to the
Queensland Tuberculosis Control Center (QTBCC). Letters and questionnaires
are sent to the treating physicians. Data requested include patient characteristics
such as age, race, occupation, and exposures and clinical data such as risk factors,
comorbidities, clinical features, site of infection, microbiology and laboratory
features, radiological features, treatment, and outcome. Physicians are asked
whether they consider the organism to be responsible for clinical disease and are
referred to guidelines to aid in this assessment. These guidelines were developed
by the QTBCC; they are in accordance with standard American Thoracic Society
(ATS) criteria (11) and were used to define disease for the purposes of the study.
Participation in this survey is voluntary.
Sputum samples were processed by a number of regional private laboratories,
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and mycobacterial isolates were referred onto the QMRL for speciation. All
public hospital sputum specimens from the greater Brisbane area were trans-
ported directly to the QMRL and processed using 4% NaOH and phosphoric
acid and concentrated using centrifugation. A mycobacterium growth indicator
tube (MGIT) (Becton Dickinson [BD]) was inoculated using 0.5 ml of sediment,
and 0.25 ml was used to inoculate solid Lowenstein-Jensen slopes. Inoculated
MGIT media were incubated at 35°C in a BD Bactec 960 machine until a positive
signal was detected. Solid media were incubated and screened weekly for the
presence of growth.
To confirm the presence of mycobacterial species, a Ziehl-Neelsen stain was
performed, followed by a multiplexed PCR targeting the 16S rRNA region. This
method is used routinely to discriminate between Mycobacterium tuberculosis,
Mycobacterium avium, Mycobacterium intracellulare, Mycobacterium abscessus,
and unspecified Mycobacterium species (33). For those identified as unspecified
Mycobacterium species, prior to 2004, further identification was performed using
a Mycobacterium avium complex (MAC) GenProbe or phenotypic identification.
In 2004, both 16S RNA sequencing and the Hain Life Sciences GenoType
Mycobacterium kit were introduced. The Hain Life Sciences GenoType Myco-
bacterium AS (additional species) kit was used to identify some isolates between
2004 and 2008. However, species identification was confirmed on all isolates
(including those pre-2004) by amplifying hypervariable regions a and b outside
the 16S region of the genome. This amplified product was sequenced using
BigDye Terminator chemistry. Analysis was performed using both GenBank and
RIDOM databases.
Susceptibility testing in 1991 was performed using the proportion method on
7H10 agar, with resistance defined as 1% of the bacterial population being
resistant to the drug. Subsequently the BD Bactec MGIT 960 method was used
for streptomycin, rifampin, isoniazid, and ethambutol by following the manufac-
turer’s instructions. Clarithromycin was tested at concentrations of 4 g/ml, 16
g/ml, and 64 g/ml, in line with CLSI guidelines.
RESULTS
Patient characteristics and distribution. M. asiaticum was
isolated from 24 patients (11 male and 13 female) between
1989 and 2007 (Fig. 1). The mean age was 54.8 years. The
biggest cluster of isolates (n  8) was centered on Townsville
in northern Queensland (Fig. 2). Fifty-eight percent of isolates
were from sputum specimens, 21% were found in bronchial
washings, 4% were found in both sputum and bronchial wash-
ings (Table 1), and 17% were from extrapulmonary sites (Ta-
ble 2). Underlying chronic lung disease was present in 65% of
patients with pulmonary isolates, namely, COPD (40%), bron-
chiectasis (20%), lung cancer, and cystic fibrosis (CF). One
patient had possible past tuberculosis, and another was on
treatment for tuberculosis. Other NTM were isolated from 5 of
20 patients with pulmonary M. asiaticum prior to, and from 4
patients after, isolation of M. asiaticum. NTM organisms were
isolated from three patients at the same time as M. asiaticum
was isolated. The most common NTM were members of MAC
and unspeciated slow growers. Isolation of non-NTM organ-
isms, the most common being Pseudomonas aeruginosa and
Staphylococcus aureus, was more frequent after isolation of M.
asiaticum.
Significance. One patient had cavitary pulmonary disease,
another had disease in the setting of bronchiectasis, 2 had
extrapulmonary disease (olecranon bursitis and lymphadeni-
tis), 6 had possible pulmonary disease, and 2 had possible
extrapulmonary disease (wound/soft tissue infections). The re-
maining isolates were not felt to be associated with NTM
disease by the treating physician or there was insufficient in-
formation available to make a judgment.
Pulmonary disease. Two patients satisfied the QTBCC and
ATS criteria for definite NTM disease due to M. asiaticum.
Patient 1 was a 52-year-old male from far north Queensland,
presenting in 1991 with a productive cough and weight loss, on
a background of smoking-related COPD. A chest X ray (CXR)
showed left upper lobe cavitation. Four of five sputa were
smear positive, and all were culture positive for M. asiaticum.
He received ethambutol, rifampin, and isoniazid for 12 months,
with pyrazinamide added for the first 2 months. In vitro sus-
ceptibilities showed susceptibility to clarithromycin, rifampin
(20 mol/ml), rifabutin, ethambutol, clofazimine, and cipro-
floxacin and resistance to rifampin (5 and 10 mol/ml). CXR
showed clearing by 3 months and further clearing at 6 months.
Sputum conversion occurred after 4 months of treatment.
FIG. 1. Numbers of patients with isolates according to year of first
isolation.
FIG. 2. Distribution of patient isolates of M. asiaticum in Queens-
land (copyright Queensland Health, Brisbane, Queensland, Australia).
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The second patient presented in late 1998 at the age of 73
years with a lifetime history of chronic productive cough and
an episode of hemoptysis. Two of three sputum samples were
smear positive for acid-fast bacilli (AFBs), 1 was smear nega-
tive, and all 3 grew M. asiaticum. CXR showed nonspecific
bronchial wall thickening, and computed tomography (CT) of
the chest revealed evidence of bronchiectasis involving the
right middle lobe and the right lower lobe. Between 1998 and
2000, she had intermittent episodes of small-volume hemopty-
sis and recurrent exacerbations partially responding to courses
of ciprofloxacin. She was managed with sputum clearance tech-
niques, chest physiotherapy, and nebulized hypertonic saline
during exacerbations, but no specific NTM therapy. Sputum
cultures from February 2000 and June 2001 were heavily smear
positive for AFBs, but no further identification was available.
A repeat CT, however, showed progression of the bronchiec-
tasis with mild to moderate bronchiectasis in both lower lobes
and the lingula. Sputum specimens continued to grow M. asi-
aticum.
In 2003 treatment was commenced with ethambutol, ri-
fampin, and clarithromycin. She developed a rash, attributed
to ethambutol after rechallenge, and ciprofloxacin was sub-
stituted. Clarithromycin was changed to azithromycin, as it
was perceived that the former was ineffective. In 2004 pro-
thionamide was added because of progressive symptoms,
and intermittent courses of ceftazidime were commenced
for Pseudomonas infection. In 2005, rifampin was ceased to
simplify treatment. Nebulized amikacin was tried but re-
sulted in dysphonia. Intravenous amikacin was therefore
given thrice weekly for 8 weeks, in combination with minocy-
cline (100 mg/day) and azithromycin (250 mg/day). In vitro
susceptibilities were done retrospectively for the purpose of
this study. The isolate was susceptible to ethambutol and cla-
rithromycin and resistant to rifampin, isoniazid, and strepto-
mycin. The patient remained on oral treatment for 2 years,
with good symptomatic response and sputum conversion.
Treatment was ceased in 2007; however, cough and sputum
increased. The October 2007 CT showed no extension of the
bronchiectasis compared to 2006. As there had been 18 months
of negative sputum cultures (except for one isolate of Myco-
bacterium gordonae, regarded as a contaminant), it was felt
her symptoms were most likely due to her underlying bron-
chiectasis. At the patient’s request azithromycin was recom-
menced thrice weekly. Sputum specimens now regularly cul-
ture Achromobacter xylosoxidans.
Possible pulmonary disease. All patients with possible pul-
monary disease had underlying lung pathology, including
COPD (n  2), CF (n  1), bronchiectasis (n  1), and lung
cancer (n  2). All the patients with underlying COPD and
lung cancer were current or past smokers. The CF and bron-
chiectasis patients were nonsmokers (Table 3).
Patients with the established risk factors of COPD and bron-
chiectasis had other NTM isolates prior to M. asiaticum, mak-
ing it hard to determine whether M. asiaticum contributed to
the pulmonary disease. The most common other NTM isolated
was M. intracellulare. Others included M. avium, Mycobacte-
rium smegmatis, Mycobacterium peregrinum, Mycobacterium
kubicae, and M. gordonae.
Clinical features were nonspecific and included cough, he-
moptysis, weight loss, and recurrent infective exacerbations.
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Radiological changes were mostly consistent with underlying
disease and included progressive bronchiectasis, nodules 5
mm, and upper lobe opacity. None of the patients had cavitary
changes.
Two of these six patients were treated for NTM disease
presumed due to MAC, with M. asiaticum considered either a
copathogen or contaminant. Drugs used included ethambutol,
rifampin, clofazimine, clarithromycin, and ciprofloxacin. The
duration of treatment was 18 to 24 months initially, followed by
further treatment if there was evidence of disease progression.
One patient died despite treatment. NTM disease together with
COPD was thought to be a contributory factor to his death. The
other patient had received treatment for NTM disease prior to
isolation of M. asiaticum, with no further treatment given after-
wards. She had evidence of progressive disease, with continued
weight loss, and developed cor pulmonale. Both lung cancer pa-
tients received treatment for their lung cancer but no treatment
for NTM disease.
Extrapulmonary isolates. The patient with olecranon bursi-
tis has been previously reported (6). He (patient 21) sustained
a left elbow laceration in August 1988 and presented with
olecranon bursitis in October 1989. It was initially deemed to
be a low-grade bursitis, and no treatment was given. By No-
vember 1989 there was persistent elbow inflammation. It was
therefore aspirated and injected with methylprednisolone. In
December 1989, it was again aspirated and treatment with
flucloxacillin was begun. Radiology showed no evidence of
osteomyelitis. The aspirate was smear negative for acid-fast
bacilli, but M. asiaticum was grown. This was sensitive to cy-
closerine and prothionamide and resistant to isoniazid, ri-
fampin, and ethambutol. Around this time the patient moved
from Townsville to a town just north of Melbourne. By January
1990 an infection had developed. He received a second course
of flucloxacillin, and the infection was treated locally with
H2O2 irrigation, povidone-iodine dressings, and immobiliza-
tion. No specific antimycobacterial treatment was given. The
wound started to heal slowly, and further swabs did not isolate
mycobacteria.
A 4-year-old girl presented with submandibular lymphade-
nitis (patient 22), and an excision biopsy demonstrated multi-
ple caseating granulomata. M. asiaticum was cultured. No fur-
ther treatment was given.
In both of the other 2 extrapulmonary cases M. asiaticum
was cultured from nonhealing wounds. The first case (patient
23) presented with a nonhealing right foot wound thought to
be from a coral cut. A wound swab grew M. asiaticum, but
biopsy revealed a basal cell carcinoma infiltrating the deep
dermis, and tissue culture grew a heavy growth of S. aureus.
Histology of the surgically excised specimen 2 months after
isolation of M. asiaticum did not reveal evidence of mycobac-
terial infection.
The second patient, an Irish tourist in north QLD, presented
with a left shin ulcer, and a wound swab grew M. asiaticum. No
TABLE 2. Clinical characteristics, treatment, and outcome of 4 patients with nonpulmonary NTM isolatesa
ID Age/sex Risk factor Specimen type M. asiaticummicrobiology Other isolates Disease Treatment Outcome
21 24/M Elbow laceration Elbow aspirate S C Nil Olecranon
bursitis
Aspiration, local steroid,
flucloxacillin
Developed sinus infection,
healed with local Rx
22 4/F Nil Submandibular node S, NA; C Nil Lymphadenitis Excised Healed
23 45/M Preexisting wound R foot swab S C S. aureus on tissue
culture
Possible wound
infection
Bx; BCC excised Good response
24 22/M Preexisting wound Wound swab, L shin S, NA; C Nil Possible wound
infection
Lost to f/u Lost to f/u
a BCC, basal cell carcinoma; Bx, biopsy; C, culture; F, female; f/u, follow up; ID, patient identification number; L, left; M, male; NA, not available; R, right; Rx,
treatment.
TABLE 3. Clinical features, treatment, and outcome of 6 patients with possible pulmonary diseasea
ID Smoker Clinical features Radiology Treatment Outcome/comments
3 Yes SOB on exertion,
minimal sputum
Nodules 5 mm, small RUL
nodular opacity, unchanged
on serial X rays; presumed
granuloma
Not treated Alive, ICU admission with type
1 respiratory failure in 2008
4 Yes NA NA 18-mo Rx for NTM; no details
specified
Deceased (NTM disease 
COPD)
5 No Recurrent infective
exacerbations
Extensive bilateral BE Not treated for M. asiaticum Alive
6 No Cough, anorexia,
wt loss
BE RML, progressed to fibrotic
and airspace change in
lingula, LUL, RUL, and
RML
Not treated for M. asiaticum; previous
treatment for other NTM
M. asiaticum isolated late in
course of NTM disease;
developed cor pulmonale
7 Yes NA Lung mass XRT Alive
8 Yes NA RUL mass Chemoradiation, excision of cerebellar
metastasis
Repeat FOB: S C
a BE, bronchiectasis; C, culture; COPD, chronic obstructive pulmonary disease; FOB, fiber optic bronchoscopy; ID, patient identification number; LUL, left upper
lobe; NA, not available; NTM, nontuberculous mycobacteria; RML, right middle lobe; RUL, right upper lobe; Rx, treatment; S, smear; SOB, shortness of breath; XRT,
radiation treatment.
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further follow-up was available, as the patient returned to
Ireland.
DISCUSSION
Although data in the literature are limited, it has already
been established that M. asiaticum is a pathogen that can be
associated with human disease. However, the nature, extent,
and spectrum of disease have not been very well described.
Data on treatment and response to treatment are also lacking,
and physicians often have to rely on “expert opinion” when
treating disease due to this slow-growing mycobacterium. To
our knowledge this is the largest series of M. asiaticum isolates
described in the literature to date.
Although M. asiaticum is rare, our study reveals a relatively
high incidence of M. asiaticum isolates in Queensland. NTM
disease as a group seems to be more prevalent in warmer
climates. In the 2000 national NTM survey, Queensland and
the Northern Territory rated highest among all Australian
states and territories for the incidence of NTM disease, with
3.8 and 4.1 reported cases per 100,000 people, respectively
(12). NTM causing nonpulmonary disease was also found to be
prevalent in Queensland (4, 13). The ideal growth conditions
for many NTM include a temperature between 10 and 45°C.
With the Tropic of Capricorn running through the center of
QLD, an ideal climate for NTM growth exists year round.
Rates of disease in Victoria and New South Wales, more-
southern states of Australia, in 2000 were 1.3 and 0.78 per
100,000, respectively (12). Distribution data for M. asiaticum
from our study confirm the observations of Blacklock et al. (5),
where 3 of 5 patients in that study lived around the Tropic of
Capricorn, 1 was born near there and moved to southern
Queensland, and 1 lived 600 km north. Most of our isolates
came from in and around this area, mostly from Townsville.
An important reservoir could be Queensland’s potable water
supplies. In 1980 Tuffley and Holbeche sampled water from
rainwater tanks in central Queensland. NTM were isolated in
32 of 141 samples (28). More-recent sampling has identified
mycobacteria in 70% of Brisbane sites sampled; however, M.
asiaticum was not isolated. Sampling in Townsville and Rock-
hampton, however, has not been performed. In a Czech study,
the authors reported that there were seasonal variations in the
occurrence of mycobacteria in drinking water, and they attributed
this to a change in water temperature (14). Given Queensland’s
climate, Queensland’s water distribution systems would provide
the ideal environment for NTM growth, including M. asiaticum.
Risk factors for M. asiaticum were similar to those observed
for other NTM species, with COPD and bronchiectasis being
the most commonly observed preexisting conditions in pulmo-
nary cases. The association between bronchiectasis and NTM
disease has been well described, and bronchiectasis is now
recognized both as a cause and effect of NTM disease (3). In
their 2005 series, Koh et al. reported that 1/3 of patients with
bilateral bronchiectasis and bronchiolitis on CT had NTM dis-
ease (13a). Furthermore, invasive NTM disease has been as-
sociated with slow progression of bronchiectasis without cavi-
tation on high-resolution CT (HRCT) (20, 26). The Lady
Windermere syndrome first described in 1992 denotes fi-
bronodular bronchiectasis most commonly occurring in thin
women 60 years old involving the right middle lobe and
lingula (21). This form of bronchiectasis without cavitation is
becoming increasingly recognized as an important pattern of
NTM pulmonary disease. The M. asiaticum cases described
previously by Blacklock et al. both had cavitary disease (5),
whereas the case described by Taylor et al. had nodular disease
(27). In our series one patient had cavitary disease (patient 1)
and at least 2 patients could well fit the pattern of Lady Win-
dermere syndrome (patients 2 and 6). Both of them developed
radiological evidence of progression of the bronchiectasis in
the presence of NTM including M. asiaticum.
Although lung cancer has not previously been considered a
predisposing condition for NTM disease, it is worth noting that
2 patients with possible M. asiaticum disease in our study had
non-small cell lung cancer (patients 7 and 8). They were
classed as having possible NTM disease on the basis that the
specimen was a bronchial washing, which is normally regarded
as sterile. The low number of patients in this study precludes us
from reaching any conclusions regarding the association be-
tween lung cancer and M. asiaticum disease/colonization. It is
hard to determine the pathogenicity of NTM in these cases.
Radiological changes are not very helpful if the focus of infec-
tion is within or in the same lobe as the tumor. Tamura et al.
reported on the coexistence of lung cancer and active pulmo-
nary mycobacteriosis. In their series 11/61 patients with lung
cancer and coexistent mycobacteriosis had foci in the same
lobe. Five of these were NTM infections, and in 3 cases the
focus of mycobacterial infection was not separately identifiable
(25). It is difficult to make the decision of whether to treat the
NTM in these cases. More often than not, as was the case in
our series, treatment for the pulmonary malignancy takes pri-
ority and the NTM is left untreated. Long-term outcomes are
also hard to assess, as survival is often limited.
In our series two patients met the QTBCC/ATS criteria for
definite pulmonary disease. Clinical features were nonspecific,
in line with what would be expected for NTM disease. In the
first case sputum conversion and cure were achieved with stan-
dard tuberculosis (TB) treatment extended to 12 months. In
the second patient remission was achieved with amikacin thrice
weekly for 8 weeks and azithromycin (250 mg/day) and mino-
cycline (100 mg/day) for 2 years. It was hard to assess response
to the standard ethambutol-rifampin-clarithromycin regimen
as the ethambutol was not tolerated. However clarithromycin-
rifampin-ciprofloxacin was not effective in controlling symp-
toms or converting sputum cultures to negative, even with the
addition of prothionamide. The duration of treatment for this
patient was difficult to determine. Symptoms recurred when
there was an attempt at stopping treatment, but it was felt that
the anti-inflammatory properties of azithromycin were control-
ling symptoms in the last year of treatment, as cultures were
repeatedly negative for mycobacteria (1, 10).
It has previously been noted that in vitro sensitivities do
not correlate well with clinical response in NTM disease (5,
27). It is therefore difficult to assess the relevance of the
susceptibilities performed. In previously published case re-
ports, patients responded to regimens using rifampin-isoniazid-
ethambutol-streptomycin, ethambutol-rifampin, and rifampin-
ethambutol-capreomycin-pyrazinamide (5, 27). Although these
observations are useful, it is hard to give specific treatment rec-
ommendations given the relatively small number of M. asiaticum
cases in the literature.
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It is also interesting to note the change in respiratory flora
after isolation of M. asiaticum (Table 1). We hypothesize that
the damage done to the lung by active NTM disease would set
the stage for colonization by other organisms. This phenome-
non appears to be common to pulmonary disease across all
NTM species.
Extrapulmonary infections in this group included lymphadeni-
tis in a child and olecranon bursitis following an elbow laceration.
NTM have long been recognized as a cause of cervical lymphad-
enitis in children (17, 30). The commonest NTM species in-
volved is the M. avium complex. Others include M. kansasii,
Mycobacterium scrofulaceum, Mycobacterium xenopi, and My-
cobacterium chelonae. Lymphadenitis due to M. asiaticum has
not been previously reported in humans, although there is a
case report of lymphadenitis due to M. asiaticum in a red-
handed tamarin (24). NTM lymphadenitis is commonly treated
with local excision, with excellent response, as was the case
with our patient. Bursitis has been previously reported with M.
kansasii, Mycobacterium szulgai, M. avium-M. intracellulare, and
M. marinum (2, 9, 16, 18, 19, 22, 23, 29). Cases are usually
treated with a combination of surgery and appropriate antimy-
cobacterial agents. To our knowledge the patient with olecra-
non bursitis is the only reported case of bursitis secondary to
M. asiaticum (6). He responded to nonspecific treatment in-
cluding drainage, regular dressings, and arm rest.
Our study had several limitations. (i) It is a relatively small
series, with only one definite case of pulmonary disease attrib-
utable to infection with M. asiaticum. (ii) Because our data
collection relied on physicians returning questionnaires, some
of the data were missing or incomplete. (iii) Although physi-
cians had access to guidelines to assess the clinical significance
of M. asiaticum, the assessment was made by the individual
physicians, who would have various levels of exposure to and
experience with patients with NTM infections.
Despite the limitations of a small case series, we have made
a number of epidemiologically and clinically relevant observa-
tions. M. asiaticum seems to be more prevalent in a warm
climate such as that of Queensland. It is often a colonizer/
contaminant, but can be responsible for pulmonary disease
including noncavitary disease. It can also be responsible for
childhood lymphadenitis and soft tissue infections. Risk factors
and clinical and radiological features are largely similar to
those observed for other NTM species. Treatment for pulmo-
nary disease is challenging, and larger series are needed to
enable specific treatment recommendations. Local excision
seems sufficient for childhood lymphadenitis, as observed for
other NTM species. Bursitis may also respond to local mea-
sures, and the isolation of M. asiaticum does not mandate
specific treatment.
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